ClinicalTrials.gg
RecruitingNCT06567821Updated Mar 11, 2026

Using Navigation to Improve Accuracy of Maxillary Balloon Sinusotomy

A Phase 2/3 interventional study of RELIEVA SPINPLUS® NAV Balloon Sinusplasty System in Chronic Maxillary Rhinosinusitis, sponsored by Cedars-Sinai Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Cedars-Sinai Medical Center · Phase 2/3, Interventional, and Other

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Rhinosinusitis with a site in United States — 11 open to participants now, 18 under way, 7 of them phase 3. Rhinosinusitis · United States.

Planned enrollment
33rd of 55
50 · median 59
Started
2024
with 6 others
Phase 2/3
3 of 71
1 open now
Primary completion
2027-10
later than 13 of 17 live
Registered
57th of 71
by date

Among the 71 studies in Rhinosinusitis with a site in United States, this one is the 33rd largest by planned enrollment of the 55 interventional ones that give a count, is one of 7 that started in 2024, is one of 3 in phase 2/3, reaches primary completion later than 13 of the 17 other live ones, and was the 57th registered.

Rhinosinusitis

252 studies on the registry are indexed under Rhinosinusitis; 70 are open to participants now.

Browse Rhinosinusitis studies →

Open to participants now

11 of the 71 studies in Rhinosinusitis with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Rhinosinusitis studies recruiting now, 15 (44%) set no upper age limit and 13 (38%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Rhinosinusitis with a site in United States, or all of them as a file.
02

Study summary

The purpose of the research is to examine the effectiveness of navigation in maxillary sinus balloon dilation for the treatment of chronic maxillary rhinosinusitis.

Read the detailed description

The purpose of the research is to examine the effectiveness of navigation in maxillary sinus balloon dilation for the treatment of chronic maxillary rhinosinusitis. Adult patients (18 and over) with a confirmed diagnosis of chronic maxillary rhinosinusitis without nasal polyposis (CRSwNP) will undergo maxillary balloon sinusotomy. Block randomization will be performed to determine which side will receive balloon sinusotomy with navigation and which will have balloon sinusotomy using traditional anatomic landmarks. Participants will be followed for approximately 1 month post-procedure for a total study participation time of approximately 3 months.

03

Conditions studied

  • Chronic Maxillary Rhinosinusitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 years of age or older
  • Candidate for primary endoscopic sinus surgery (ESS) for chronic maxillary rhinosinusitis without nasal polyposis (CRSwNP)
  • Failed medical (non-surgical) therapy

Exclusion criteria

Exclusion Criteria:

  • History of previous sinus surgery
  • Presence of nasal polyps
  • Extensive sinonasal osteogeneis
  • Cystic fibrosis
  • Presence of sinonasal tumors
  • Any records flagged "break the glass" or "research opt out."
  • Any additional finding which in the opinion of the investigator precludes patient from participating in the study
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Interventions

  • DeviceRELIEVA SPINPLUS® NAV Balloon Sinusplasty System

    The non-navigated device being used is the RELIEVA SPINPLUS® Balloon Sinusplasty System and the navigated device being used is the RELIEVA SPINPLUS® NAV Balloon Sinusplasty System. Both devices being used are standard devices that are currently FDA approved and used in practice for sinus dilation at Cedars-Sinai Medical Center.

    Also known as: RELIEVA SPINPLUS® Balloon Sinusplasty System

06

What researchers measure

Primary outcomes

  1. Success Rate

    There is a 30% expected improvement of success, in favor of navigation over non-navigation balloon sinuplasty devices.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Oct 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Aug 23, 2024
StartActual
Sep 4, 2024
Primary completionEst.
Oct 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06567821
Responsible party
Dennis Tang (Physician, Cedars-Sinai Medical Center) — Principal investigator
First posted
Aug 23, 2024
Start date
Sep 4, 2024
Primary completion
Oct 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 11, 2026

Study contacts

Shruti Shantharam
Contact
Shruti.Shantharam@csmns.org
5627873255

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion